SCA
TVRD

SAC Capital Advisors’s Tvardi Therapeutics TVRD Stock Holding History

SAC Capital Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-310
Closed -$208K – 1086
2014
Q1 		$208K Buy
+310
New +$183K ﹤0.01% 1564

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AAM
Aberdeen Asset Management Aberdeen, United Kingdom $30B AUM 22.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

SAC Capital Advisors's TVRD Position: Q2 2014 in Review

SAC Capital Advisors sold out of Tvardi Therapeutics (TVRD) in Q2 2014, closing a stake of 310 shares — an estimated $208K sold.

SAC Capital Advisors first reported a position in TVRD in Q1 2014 and held it in 1 quarter. The position peaked at $208K in Q1 2014. 49 funds tracked by Wall St. Rank hold TVRD as of Q2 2014.

  • SAC Capital Advisors reported no remaining Tvardi Therapeutics position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 310 Tvardi Therapeutics shares in Q2 2014, an estimated $208K.
  • SAC Capital Advisors first reported a position in Tvardi Therapeutics in Q1 2014 and held it in 1 quarter.
  • SAC Capital Advisors's Tvardi Therapeutics position peaked at $208K in Q1 2014.
  • 49 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.